Integrative transcriptome analysis identifies MYBL2 as a poor prognosis marker for osteosarcoma and a pan-cancer marker of immune infiltration

Xinzhu Qiu; Hongbo He; Hao Zeng; Xiaopeng Tong; Can Zhang; Yupeng Liu; Zhan Liao; Qing Liu

doi:10.1016/j.gendis.2023.04.035

您当前的位置：

首页 >

文章列表页 >

Integrative transcriptome analysis identifies MYBL2 as a poor prognosis marker for osteosarcoma and a pan-cancer marker of immune infiltration

Full-length article | 更新时间：2024-02-04

- Integrative transcriptome analysis identifies MYBL2 as a poor prognosis marker for osteosarcoma and a pan-cancer marker of immune infiltration
- Integrative transcriptome analysis identifies MYBL2 as a poor prognosis marker for osteosarcoma and a pan-cancer marker of immune infiltration
- Genes & Diseases 2024年11卷第3期
- 作者机构：
  
  1. Department of Orthopaedics, Xiangya Hospital, Central South University,Hunan,Changsha,China,410008
  2. Department of Sports Medicine, Research Center of Sports Medicine, Xiangya Hospital, Central South University,Hunan,Changsha,China,410008
  3. National Clinical Research Center for Geriatric Disorders, Xiangya Hospital,Hunan,Changsha,China,410008
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2023.04.035
  中图分类号：
- 纸质出版日期：2024，
  
  网络出版日期：2024-5-1，
扫描看全文
Xinzhu Qiu, Hongbo He, Hao Zeng, 等. Integrative transcriptome analysis identifies MYBL2 as a poor prognosis marker for osteosarcoma and a pan-cancer marker of immune infiltration[J]. Genes & Diseases, 2024,11(3).

Xinzhu Qiu, Hongbo He, Hao Zeng, et al. Integrative transcriptome analysis identifies MYBL2 as a poor prognosis marker for osteosarcoma and a pan-cancer marker of immune infiltration[J]. Genes & Diseases, 2024,11(3).
Xinzhu Qiu, Hongbo He, Hao Zeng, 等. Integrative transcriptome analysis identifies MYBL2 as a poor prognosis marker for osteosarcoma and a pan-cancer marker of immune infiltration[J]. Genes & Diseases, 2024,11(3). DOI： 10.1016/j.gendis.2023.04.035.

Xinzhu Qiu, Hongbo He, Hao Zeng, et al. Integrative transcriptome analysis identifies MYBL2 as a poor prognosis marker for osteosarcoma and a pan-cancer marker of immune infiltration[J]. Genes & Diseases, 2024,11(3). DOI： 10.1016/j.gendis.2023.04.035.

摘要

Abstract

MYBL2 (MYB proto-oncogene like 2) is an emerging prognostic marker for malignant tumors

and its potential role in osteosarcoma and its relationship with immune infiltration in pan-cancer is yet to be elucidated. We constructed a transcription factor activity profile of osteosarcoma using the single-cell regulatory network inference algorithm based on single-cell RNA sequencing data obtained from the Gene Expression Omnibus. Subsequently

we calculated the extent of MYBL2 activation in malignant proliferative osteoblasts. We also explored the association between MYBL2 and chemotherapy resistance in osteosarcoma. Furthermore

we systematically correlated MYBL2 with immunological signatures in the tumor microenvironment in pan-cancer

including immune cell infiltration

immune checkpoints

and tumor immunotherapy prognosis. Finally

we developed and validated a risk score (MRGS)

derived an osteosarcoma risk score nomogram based on MRGS

and tested its ability to predict prognosis. MYBL2 and gene enrichment analyses in osteosarcoma and pan-cancer revealed that MYBL2 was positively correlated with cell proliferation and tumor immune pathways. MYBL2 expression positively correlated with SLC19A1 in pan-cancer and osteosarcoma cell lines. Pan-cancer immune infiltration analysis revealed that MYBL2 was correlated with myeloid-derived suppressor cells

Th2 cell infiltration

CD276

RELT gene expression

and tumor mutation burden. In summary

MYBL2 regulates proliferation

progression

and immune infiltration in osteosarcoma and pan-cancer. Therefore

we found that MYBL2 could be used as a potential marker for predicting the osteosarcoma prognosis. Patients with osteosarcoma and high MYBL2 expression are theoretically more sensitive to methotrexate. An osteosarcoma prognostic nomogram can provide new ideas in the search for osteosarcoma prognostic markers.

关键词

Keywords

BiomarkerImmune checkpointMYBL2OsteosarcomaPan-cancer

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

The generation and use of animal models of osteosarcoma in cancer research

Aberrant LETM1 elevation dysregulates mitochondrial functions and energy metabolism and promotes lung metastasis in osteosarcoma

Vitamin D-binding protein in plasma microglia-derived extracellular vesicles as a potential biomarker for major depressive disorder

Transcriptomic and machine learning analyses identify hub genes of metabolism and host immune response that are associated with the progression of breast capsular contracture

Cellular senescence-driven transcriptional reprogramming of the MAFB/NOTCH3 axis activates the PI3K/AKT pathway and promotes osteosarcoma progression